temsirolimus. 18 In this study, progression-free survival was not different between the treatment arms (hazard rate, 0.89; 95% CI, 0.75–1.05; long-rank P = .18). The reasons for the difference in the outcomes of the 2 endocrine therapy with or without an
Search Results
Metastatic Breast Cancer, Version 1.2012
Featured Updates to the NCCN Guidelines
Robert W. Carlson, D. Craig Allred, Benjamin O. Anderson, Harold J. Burstein, Stephen B. Edge, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Lori J. Goldstein, William J. Gradishar, Daniel F. Hayes, Clifford A. Hudis, Steven Jay Isakoff, Britt-Marie E. Ljung, David A. Mankoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Lori J. Pierce, Elizabeth C. Reed, Mary Lou Smith, Hatem Soliman, George Somlo, Richard L. Theriault, John H. Ward, Antonio C. Wolff, Richard Zellars, Rashmi Kumar, and Dorothy A. Shead
Toni K. Choueiri and Robert J. Motzer
–naïve patients with mRCC, “optimal” first-line options include sunitinib, pazopanib, the combination of bevacizumab and interferon-alpha, and temsirolimus (in poor-risk RCC only). These recommendations are all based on significantly improving efficacy over the
Matthew G. Fury and David G. Pfister
and related compounds (e.g., everolimus, temsirolimus) that inhibit the serine/threonine kinase activity of mTOR in the mTORC1 compex, 65 Temsirolimus reduces growth of HNSCC cell lines in xenograft models, 66 and everolimus inhibits tumor growth in
Robert J. Motzer, Neeraj Agarwal, Clair Beard, Graeme B. Bolger, Barry Boston, Michael A. Carducci, Toni K. Choueiri, Robert A. Figlin, Mayer Fishman, Steven L. Hancock, Gary R. Hudes, Eric Jonasch, Anne Kessinger, Timothy M. Kuzel, Paul H. Lange, Ellis G. Levine, Kim A. Margolin, M. Dror Michaelson, Thomas Olencki, Roberto Pili, Bruce G. Redman, Cary N. Robertson, Lawrence H. Schwartz, Joel Sheinfeld, and Jue Wang
-779, a novel macrolide anti-tumor agent, on growth of human tumor cells in vitro and in nude mouse xenografts in vivo [abstract] . Proc Am Assoc Cancer Res 1999 ; 40 : Abstract 301 . 39 Hudes G Carducci M Tomczak P . Temsirolimus
Robert Torrey, Philippe E. Spiess, Sumanta K. Pal, and David Josephson
favorable side effect profile. 49 , 52 Six different targeted therapy medications have been approved by the FDA for the treatment of patients with advanced RCC: sunitinib, sorafenib, pazopanib, temsirolimus, everolimus, and bevacizumab combined with
Rashmi Chugh
translation. 56 Multiple studies are examining the role of mTOR inhibition in sarcomas. The Sidney Kimmel Comprehensive Cancer Center is conducting a phase I/II study to evaluate the safety and efficacy of temsirolimus and liposomal doxorubicin in patients
Barbara Burtness
as sorafenib and vemurafenib, have been associated with hand-foot skin reaction (HFSR), 5 and the newer BRAF inhibitor regorafenib “has some pretty dramatic skin manifestations,” noted Dr. Burtness. mTOR inhibitors, such as temsirolimus and
Eric Jonasch
bevacizumab, high-dose interleukin-2 for selected patients, and temsirolimus. Ipilimumab plus nivolumab was just added to the NCCN Guidelines as a category 2A recommendation for subsequent therapy in patients with metastatic RCC. Best supportive care is
Saby George, Roberto Pili, Michael A. Carducci, and Jenny J. Kim
default standard for comparison in first-line trials that led to the approval of 3 targeted agents in RCC, 6 , 9 , 24 including the phase III trials of sunitinib and temsirolimus. Because of the improved progression-free survival seen in the experimental
NCCN Guidelines Insights: Kidney Cancer, Version 2.2020
Featured Updates to the NCCN Guidelines
Robert J. Motzer, Eric Jonasch, M. Dror Michaelson, Lakshminarayanan Nandagopal, John L. Gore, Saby George, Ajjai Alva, Naomi Haas, Michael R. Harrison, Elizabeth R. Plimack, Jeffrey Sosman, Neeraj Agarwal, Sam Bhayani, Toni K. Choueiri, Brian A. Costello, Ithaar H. Derweesh, Thomas H. Gallagher, Steven L. Hancock, Christos Kyriakopoulos, Chad LaGrange, Elaine T. Lam, Clayton Lau, Bryan Lewis, Brandon Manley, Brittany McCreery, Andrew McDonald, Amir Mortazavi, Phillip M. Pierorazio, Lee Ponsky, Bruce G. Redman, Bradley Somer, Geoffrey Wile, Mary A. Dwyer, CGC, Lydia J. Hammond, and Griselda Zuccarino-Catania
the next era. Currently recommended first-line targeted therapy options in the NCCN Guidelines are single-agent TKIs or VEGF inhibitors, including pazopanib, 29 sunitinib, 30 axitinib, 31 and cabozantinib, 32 or temsirolimus, which targets mTOR. 33
